

TRANSMITTAL LETTER TO THE UNITED STATES

DESIGNATED/ELECTED OFFICE (DO/EO/US)

CONCERNING A FILING UNDER 35 U.S.C. 371

1951

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

10/030278

INTERNATIONAL APPLICATION NO.

PCT/DE 00/02231

INTERNATIONAL FILING DATE

JULY 7, 2000

PRIORITY DATE CLAIMED

JULY 9, 1999

TITLE OF INVENTION

PRESERVATIVE FOR PERISHABLE PREPARATIONS PARTICULARLY FOR COSMETIC AND
PHARMACEUTICAL FORMULATIONS

APPLICANT(S) FOR DO/EO/US

Susanne KESSLER, Sean LEE

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 18 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☒ Certificate of Mailing by Express Mail
19. ☐ Other items or information:

ET 755324109US

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.01) 10/030278	INTERNATIONAL APPLICATION NO. PCT/DE 00/02231	ATTORNEY'S DOCKET NUMBER 1951
--	---	---

20. The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :					
<input type="checkbox"/>	Search Report has been prepared by the EPO or JPO	\$930.00			
<input type="checkbox"/>	International preliminary examination fee paid to USPTO (37 CFR 1.482)	\$720.00			
<input type="checkbox"/>	No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))	\$790.00			
<input checked="" type="checkbox"/>	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$1,070.00			
<input type="checkbox"/>	International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)	\$98.00			
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	9 - 20 =	0	x \$18.00	\$0.00	
Independent claims	2 - 3 =	0	x \$80.00	\$0.00	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$890.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input type="checkbox"/>				\$0.00	
SUBTOTAL =				\$890.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 +				\$0.00	
TOTAL NATIONAL FEE =				\$890.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$890.00	
				Amount to be:	
				refunded	\$
				charged	\$

- ☐ A check in the amount of _____ to cover the above fees is enclosed.
- ☒ Please charge my Deposit Account No. **19-4675** in the amount of **\$890.00** to cover the above fees.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **19-4675** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

**STRIKER, STRIKER & STENBY
103 EAST NECK ROAD
HUNTINGTON, NEW YORK 11743**

SIGNATURE

MICHAEL J. STRIKER

NAME

27233

REGISTRATION NUMBER

JANUARY 7, 2002

DATE

UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Group: Attorney Docket # 1951

Applicant(s) : KESSLER, S., ET AL

Serial No. :

Filed :

For : PRESERVATIVE FOR PERISHABLE
PREPARATIONS...

SIMULTANEOUS AMENDMENT

January 4, 2002

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

S I R S:

Simultaneously with filing of the above identified application
please amend the same as follows:

In the Claims:

Cancel all claims without prejudice.

Substitute the claims attached hereto.

REMARKS:


This Amendment is submitted simultaneously with filing of the above identified
application.

20020103 09:00:00

With the present Amendment applicant has amended the claims so as to eliminate their multiple dependency.

Consideration and allowance of the present application is most respectfully requested.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Michael J. Striker', is written over the printed name.

Michael J. Striker
Attorney for Applicant(s)
Reg. No. 27233

20050710 08205001

PATENT CLAIMS

1. Preservative, characterized in that it comprises bioactive glass.
2. Preservative according to Claim 1, characterized in that the bioactive glass has a particle size d_{50} of $\leq 10 \mu\text{m}$.
3. Preservative according to Claim 1, characterized in that the bioactive glass has a particle size d_{50} of $\leq 5 \mu\text{m}$.
4. Preservative according to ^{claim 1}one of the preceding claims, characterized in that it is present in an amount of 10 wt.%, based on the solids content of the preparation to be preserved.
5. Preservative according to ^{claim 1}one of the preceding claims, characterized in that the bioactive glass comprises 40 - 60 wt.% of SiO_2 , 10 - 30 wt.% of CaO , 10 - 35 wt.% of Na_2O , 2 - 8 wt.% of P_2O_5 , 0 - 25 wt.% of CaF_2 , 0 - 10 wt.% of B_2O_3 , 0 - 8 wt.% of K_2O and/or 0 - 5 wt.% of MgO , based on the total weight of the glass.
6. Preservative according to ^{claim 1}one of the preceding claims, characterized in that it comprises a protic solvent.
7. Use of bioactive glass for preserving perishable merchandise.
8. Use according to Claim 7, characterized in that the merchandise is a cosmetic and/or pharmaceutical preparation.
9. Use according to Claim 7 ^{or 8} characterized in that the preparation is a cream, lotion, lipstick, make-up composition and/or tincture.

20050110 13:20:00

PATENT CLAIMS

1. Preservative, characterized in that it comprises bioactive glass.
2. Preservative according to Claim 1, characterized in that the bioactive glass has a particle size d_{50} of $\leq 10 \mu\text{m}$.
3. Preservative according to Claim 1, characterized in that the bioactive glass has a particle size d_{50} of $\leq 5 \mu\text{m}$.
4. Preservative according to claim 1, , characterized in that it is present in an amount of 10 wt.%, based on the solids content of the preparation to be preserved.
5. Preservative according to claim 1, , characterized in that the bioactive glass comprises 40 - 60 wt.% of SiO_2 , 10 - 30 wt.% of CaO , 10 - 35 wt.% of Na_2O , 2 - 8 wt.% of P_2O_5 , 0 - 25 wt.% of CaF_2 , 0 - 10 wt.% of B_2O_3 , 0 - 8 wt.% of K_2O and/or 0 - 5 wt.% of MgO , based on the total weight of the glass.
6. Preservative according to claim 1, , characterized in that it comprises a protic solvent.
7. Use of bioactive glass for preserving perishable merchandise.
8. Use according to Claim 7, characterized in that the merchandise is a cosmetic and/or pharmaceutical preparation.
9. Use according to Claim 7 characterized in that the preparation is a cream, lotion, lipstick, make-up composition and/or tincture.

WO 01/03650

PCT/DE 00/02231

PRESERVATIVE FOR PERISHABLE PREPARATIONS, PARTICULARLY FOR COSMETIC AND PHARMACEUTICAL FORMULATIONS

Description:

The invention relates to preservatives and to their use for preserving perishable preparations, particularly cosmetic and pharmaceutical compositions.

It is known to treat many perishable goods, such as foodstuffs, drugs etc. with chemical and particularly organo-chemical preservatives to extend their useful life.

This is particularly true also for cosmetic preparations that come in contact with the skin. In this case, namely during application to the skin or, in particular, when the preparation is manually removed from the jar or during the use of a lipstick, bacteria are introduced into the preparations. In the skin-compatible environment prevailing in cosmetic preparations, bacteria introduced in this manner can undergo rapid multiplication so that even after a few days their concentration can become intolerably high. The same problem also arises with cosmetic preparations stored in bottles or tubes. Although in this case, because of less contact with the skin, contamination with bacteria during removal from the container is less pronounced, contact of bacteria-bearing skin with the preparation cannot be avoided and, hence, these forms of application are also subject to rapid contamination. For this reason, it is necessary to provide such commercial preparations with bactericides or bacteriostatic agents. Such substances, however, are cytotoxic and, furthermore, are allergenic in a large number of individuals.

To ensure proper manufacturing practice worldwide, in 1968 WHO issued "Good Manufacturing Practice" (GMP). According to these guidelines, product hygiene and quality control, among other things, are to be ensured and impurities avoided. In the meantime, the GMP has been complemented by "Good Storage Practice" (GSP), valid particularly in the pharmaceutical and cosmetic industries, to ensure proper product storage.

Thus, according to US-A 5 766 611, an attempt has been made to use as a preservative a soluble glass that release silver, zinc and/or copper. These substances released by the glass also act as cell poisons and thus are cytotoxic. Hence, constant contact with such a preservative is not safe.

It is already known to use bioactive glass for oral care. For example, tooth pastes are known which promote the remineralization of teeth. US-A 5 834 008 describes the use of bioglass for healing wounds. For example, by the application of this type of glass, it is possible to bring about the healing of non-healing, ulcerating wounds, particularly in diabetics and stroke patients.

10030278-010001

J. Allen, H. Neumann and M. Wilson described the inhibition of bacterial colonization by using Bioglas® 45 S 5 with a particle size of 355 - 500 μm . Normal glass beads (window glass) with a comparable particle size of 455 - 600 μm showed no antibacterial action.

The essential properties of bioactive glass are known to those skilled in the art and are described, for example, in US-A 5 074 916. According to this patent, bioactive glass differs from conventional lime-sodium silicate glasses in that it binds to living tissues.

Bioactive glass is available in the United States, for example under the tradename "Bioglas®", from US Biomaterials Corp., Alachua, FL 32615, USA. This is a glass which in contact with an organism undergoes a special biological reaction. In contact with a body fluid, it exchanges ions with this fluid. This ion exchange causes the release of sodium ions and calcium ions which within a few minutes form on the glass a layer of silica gel leading to the formation of a hydroxy-carbonate-apatite layer which is identical to the mineral phase of bone. Hydroxy-carbonate-apatite is then formed, and the cells form collagen which becomes embedded in this layer. This produces a physico-chemical bond between the bioactive glass and the tissue or the bone material, which brings about faster bone regeneration. In this regard, it has been shown in animal studies that Bioglas® is nearly as effective as the transplantation of parts of a person's own bone.

The use of bioactive glass in combating acne is also known. To this end, a preparation containing bioactive glass is applied to the areas affected by acne, which has a positive effect on the inflammations. Also to be mentioned in this regard are the publications by John E. Rectenwald, L.L. Moldawer, Sean Lee et al. in Infection and Immunity (submitted for publication) and [Proceedings of the] 19th Annual Meeting of the Surgical Infection Society, Seattle, April 29 to May 1, 1999, which state that bioglass brings about the formation or secretion of the inflammation-inhibiting hormone interleukin 6 (IL 6) and suppresses the inflammation-promoting cytokines $\text{TNF-}\alpha$, $\text{IL-1-}\alpha$ and IL-10.

Moreover, E. Allen et al. (Department of Microbiology and Periodontology, Eastman Dental Institute) reported that the bioactive glass Bioglas® 45-S-5 obtainable from U.S. Biomaterials, Alachua, FL 32615, USA, exhibits antibacterial activity not shown by normal glass beads (window glass).

Hence, the object of the invention is to provide a preservative agent which in contrast to previously known agents exerts no negative application effects, particularly when applied to the skin.

According to the invention, this objective is reached by means of a preservative containing bioactive glass.

Bioactive glasses have been known for a long time and have been described in summary form, for example, by Larry L. Hench and John. K. West in "Biological Applications of Bioactive Glasses", Life Chemistry Reports 1996, vol. 13, pp. 187-241, or in "An Introduction to Bioceramics", L. Hench and

J. Wilson, eds., World Scientific, New Jersey (1993). Bioactive glasses, in contrast to conventional glasses, are characterized in that they are soluble in aqueous media and that they form a layer of hydroxyapatite on their surface. Most current bioactive glasses are prepared either as fusible glass, in which case they contain much less SiO_2 and much more sodium than normal window or bottle glasses, or they are sol-gel glasses which then, in contrast to fusible glasses, contain a high amount of silicon oxide and a small amount of sodium or no sodium at all.

Bioactive silicon-containing glass or bioactive glass is a material which comprises silicon oxide or silicon hydroxide and which facilitates the formation and transfer of SiOH groups. Hence, bioactive silicon-containing glass can be, for example, a bioactive glass derived from a mixture of silicon oxide or silicon hydroxide and one or more elements of the group comprising sodium, potassium, calcium, magnesium, boron, titanium, aluminum as well as anions containing nitrogen, phosphorus and fluorine. Moreover, it can be, for example, a sodium silicate of the water glass type or silica gel or a SiOH groups-containing solution or a silicon oxide or silicon hydroxide comprising hydroxyapatite as well as a silica gel containing calcium and phosphorus. One of the essential common features of bioactive silica gel-containing glass is its ability to form and to transfer SiOH groups. Moreover, it contains calcium ions and phosphate ions.

The bioactive glass contained according to the invention is preferably a conventional bioactive glass, well known to those skilled in the art. Such glasses usually contain SiO_2 , a high amount of Na_2O and CaO as well as phosphorus, the latter in a high molar ratio of calcium to phosphorus, said ratio in most, but not necessarily all, cases having a value of about five. When such bioactive glasses come in contact with water or with a body fluid, they give rise to special reactions, namely the sodium and calcium ions of the glass are exchanged for H^+ ions from the solution by a cation-exchange reaction. As a result, a silanol groups-presenting surface is formed on which sodium hydroxide and calcium hydroxide accumulate. The increase in hydroxyl ion concentration at the glass surface now brings about a further reaction with the SiO_2 network giving rise to additional silanol groups which can also lie more deeply in the glass.

Because of the high, alkaline pH in the interstitial glass space, a mixed hydroxyapatite phase is formed from CaO and P_2O_5 and crystallizes on the SiO_2 surface. In biological materials, this phase binds to mucopolysaccharides, collagens and glycoproteins.

The molar ratio of calcium to phosphorus is preferably > 2 and particularly > 3 and preferably < 30 and particularly < 20 , a ratio of < 10 being particularly preferred.

Particularly preferred are preservatives with bioactive glass particles containing SiO_2 , CaO , Na_2O , P_2O_5 , CaF_2 , B_2O_3 , K_2O and/or MgO . If the preservative agent contains bioactive particles of fusible glass, these particles preferably contain 40 - 60 wt.% of SiO_2 , 10 - 30 wt.% of CaO , 10 - 35 wt.% of Na_2O , 2 - 8 wt.% of P_2O_5 , 0 - 25 wt.% of CaF_2 , 0 - 10 wt.% of B_2O_3 , 0 - 8 wt.% of K_2O and/or 0 - 5 wt.%

of MgO, based on the total weight of the glass.

If the bioactive glass is a fusible glass, then the upper limit of the silicon dioxide it contains is 60 wt.% and preferably 55 wt.%, an upper limit of 50 wt.% being particularly preferred. The sodium oxide content is preferably higher than 15 wt.% and particularly higher than 18 wt.%. A sodium oxide content of > 20 wt.% is particularly preferred.

If the bioactive glass contained in the preservative of the invention has been produced by the sol-gel process, its silicon dioxide content can be significantly higher than in fusible glasses and its sodium oxide content can be nil. Bioactive glasses made by the sol-gel process preferably contain 40 to 90 wt.% of SiO_2 , 4 to 45 wt.% of CaO, 0 to 10 wt.% of Na_2O , 2 to 16 wt.% of P_2O_5 , 0 to 25 wt.% of CaF_2 , 0 to 4 wt.% of B_2O_3 , 0 to 8 wt.% of K_2O and/or 0 to 5 wt.% of MgO.

The phosphorus oxide content of both previously described kinds of bioactive glass is preferably at least 2 wt.% and particularly at least 4 wt.%.

In a preferred embodiment of the invention, the soluble bioactive glass does not contain or release toxic metal cations such as Ag^+ , Cu^{2+} , Cu^+ and/or Zn^{2+} etc. in toxic concentrations. To achieve synergistic effects, however, it may in some cases be desirable to add also a biocidal glass that does release toxic cations.

The bioactive glass itself is a material having a more or less round shape like, for example, sand. Such particles can have a size of up to about 0.5-1 mm, but preferably are substantially smaller. The common particle size is $\leq 400 \mu\text{m}$ and particularly $\leq 200 \mu\text{m}$, particles having a size of $\leq 100 \mu\text{m}$, preferably $\leq 90 \mu\text{m}$ and particularly $\leq 60 \mu\text{m}$ or $\leq 20 \mu\text{m}$ being especially advantageous. Preferred particles have a diameter d_{50} of $\leq 10 \mu\text{m}$, preferably $\leq 5 \mu\text{m}$ and particularly $\leq 2 \mu\text{m}$. The higher the surface-to-weight or surface-to-volume ratio, the higher is the biocidal activity of the particles.

In a preferred embodiment of the invention, the bioactive glass is used to preserve cosmetic preparations. Preferred for this purpose is a fine-particle bioactive glass with particle size $d_{50} \leq 5 \mu\text{m}$ and particularly $\leq 2 \mu\text{m}$. Preferred cosmetic preparations are, in particular, creams, make-up compositions, lipsticks as well as lotions and ointments. The moisture contained in these preparations further enhances the microbicidal activity of the bioactive glass.

The biocidal preservative of the invention is contained in the preparation to be preserved preferably in an amount of up to 25 wt.% and particularly up to 10 wt.%, based on the solids content of the preparation to be preserved. Upper limits of 7 wt.% or 5 wt.%, however, are preferred, 3 wt.% being particularly preferred. The lower limit values are 0.01 wt.% and particularly 0.1 wt.%, with 0.5 wt.% or 1 wt.% particularly preferred as the lower limit of the effective amount.

Surprisingly, we have now found that such preparations can be preserved with bioactive glass in an outstanding manner without it being necessary to add skin-irritating, cytotoxic or sometimes allergenic chemical preservatives. Moreover, an additional care effect is achieved as a result of the ability of bioactive glass to promote healing and particularly also to inhibit inflammation.

In special cases, however, it may be desirable to add the preservative of the invention to preparations rendered storage-stable with a common preservative so as to achieve a synergistic effect.

The preservative is preferably added to a proton-containing solvent, particularly to an aqueous and/or alcoholic solvent. It is also possible, however, to use the preservative in an aprotic solvent provided such a medium allows the release of the soluble cations of the glass. Preferred aprotic solvents are ketones such as acetone, fats, waxes, oils and the corresponding liquid or solid hydrocarbons. The preservative of the invention is also particularly well suited for preserving water-in-oil and oil-in-water emulsions.

Liquid cosmetic preparations with an alcohol content insufficient for preservation can also be preserved with bioactive glass. In this case, it is preferred to use a glass with a refractive index equal to that of the liquid. In this manner, the added glass is "invisible" to the consumer. To achieve a cosmetic effect, however, the glass can intentionally be made visible in a desired manner, for example by coloring.

205070 2220001

PATENT CLAIMS

1. Preservative, characterized in that it comprises bioactive glass.
2. Preservative according to Claim 1, characterized in that the bioactive glass has a particle size d_{50} of $\leq 10 \mu\text{m}$.
3. Preservative according to Claim 1, characterized in that the bioactive glass has a particle size d_{50} of $\leq 5 \mu\text{m}$.
4. Preservative according to one of the preceding claims, characterized in that it is present in an amount of 10 wt.%, based on the solids content of the preparation to be preserved.
5. Preservative according to one of the preceding claims, characterized in that the bioactive glass comprises 40 - 60 wt.% of SiO_2 , 10 - 30 wt.% of CaO , 10 - 35 wt.% of Na_2O , 2 - 8 wt.% of P_2O_5 , 0 - 25 wt.% of CaF_2 , 0 - 10 wt.% of B_2O_3 , 0 - 8 wt.% of K_2O and/or 0 - 5 wt.% of MgO , based on the total weight of the glass.
6. Preservative according to one of the preceding claims, characterized in that it comprises a protic solvent.
7. Use of bioactive glass for preserving perishable merchandise.
8. Use according to Claim 7, characterized in that the merchandise is a cosmetic and/or pharmaceutical preparation.
9. Use according to Claim 7 or 8, characterized in that the preparation is a cream, lotion, lipstick, make-up composition and/or tincture.

DECLARATION AND POWER OF ATTORNEY FOR NATIONAL STAGE OF PCT PATENT APPLICATION

As a below-named inventor, I hereby declare that:

Susanne KESSLER
Sean LEE

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **PRESERVATIVE FOR PERISHABLE PREPARATIONS, PARTICULARLY FOR COSMETIC AND PHARMACEUTICAL FORMULATIONS** the specification of which was filed as PCT International Application number PCT/DE 00/02231 on July 7, 2000.

I hereby state that I believe the named inventor or inventors in this Declaration to be the original and first inventor or inventors of the subject matter which is claimed and for which a patent is sought.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365 (b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior foreign application(s):

Priority claimed:

<u>199 32 239.2</u>	<u>GERMANY</u>	<u>JULY 9, 1999</u>	<u>X</u>	
(Number)	(Country)	(Date filed)	Yes	No
<u> </u>	<u> </u>	<u> </u>	<u>Yes</u>	<u>No</u>
(Number)	(Country)	(Date filed)	Yes	No

As a named inventor, I hereby appoint the following attorney to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Michael J. Striker, Reg. No. 27233

Direct all telephone calls to Striker, Striker & Stenby at telephone no.: (631) 549 4700 and address and all correspondence to:

STRIKER, STRIKER & STENBY
103 East Neck Road
Huntington, New York 11743
U.S.A.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statement

may jeopardize the validity of the application or any patent issued thereon.

Signature: <i>Susanne Kessler</i>	Date: <i>19.12.2002</i>	Residence and Full Postal Address: Johannisweg 23 84030 Ergolding Germany <i>DEX</i>
Full Name of First or Sole Inventor: Susanne KESSLER	Citizenship: GERMAN	
Signature: <i>Sean Lee</i>	Date: <i>07.01.02</i>	Residence and Full Postal Address: Oberlinstrasse 17 76227 Karlsruhe Germany <i>DEX</i>
Full Name of Second Inventor: Sean LEE	Citizenship: GERMAN USA	
Signature: <i>[Signature]</i>	Date: <i>[Date]</i>	Residence and Full Postal Address:
Full Name of Third Inventor:	Citizenship:	
Signature:	Date:	Residence and Full Postal Address:
Full Name of Fourth Inventor:	Citizenship:	
Signature:	Date:	Residence and Full Postal Address:
Full Name of Fifth Inventor:	Citizenship:	
Signature:	Date:	Residence and Full Postal Address:
Full Name of Sixth Inventor:	Citizenship:	
Signature:	Date:	Residence and Full Postal Address:
Full Name of Seventh Inventor:	Citizenship:	
Signature:	Date:	Residence and Full Postal Address:
Full Name of Eighth Inventor:	Citizenship:	
Signature:	Date:	Residence and Full Postal Address:
Full Name of Ninth Inventor:	Citizenship:	

100

200

20051010 14:00:00